Boundless Bio, Inc. (BOLD) stock

BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30

$2.46+0.00 (0.00%)

Close on Nov 12, 2026Market cap $55.96MP/E –Yield –

Boundless Bio gross margin

Gross margin is gross profit as a percentage of revenue.

Boundless Bio has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?